Preparation of human single-chain variable fragment
antibodies against anaplastic thyroid carcinoma, and single photon emission‑computed tomography/computed tomography imaging in tumor-bearing nude mice

Liu,Qian; Pang,Hua; Liu,Qiong; Zhou,Jing; Liu,Ying

doi:10.3892/or.2017.5550

Preparation of human single-chain variable fragment antibodies against anaplastic thyroid carcinoma, and single photon emission‑computed tomography/computed tomography imaging in tumor-bearing nude mice

Authors:
- Qian Liu
- Hua Pang
- Qiong Liu
- Jing Zhou
- Ying Liu
View Affiliations

Affiliations: Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: April 5, 2017 https://doi.org/10.3892/or.2017.5550
Pages: 2980-2986

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anaplastic thyroid carcinoma (ATC) is the most aggressive malignant thyroid tumor with the worst prognosis, and the response to treatment is poor. We investigated soluble human single-chain variable fragment (scFv) which provides unique information for diagnostics, and for monitoring and optimizing responses to therapy. Enzyme-linked immunosorbent assay (ELISA) was used to detect the expression of scFv. The expression and relative molecular mass of soluble scFv were assessed by sodium dodecyl sulfate‑polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting, respectively. The chloramine T method was used to label scFv with 131I. The labeling rate and the radiochemical purity were determined. To analyze the distribution of 131I‑scFv in body tissues and organs of nude mice, static single photon emission-computed tomography (SPECT) imaging and single photon emission‑computed tomography/computed tomography (SPECT/CT) image fusion were performed. The relative molecular mass of soluble scFv was ~29 kDa. The labeling rate was 91.64% and the radiochemical purity was 93.3±0.32%. SPECT imaging revealed that 131I-scFv selectively accumulated in tumor tissue. In addition, SPECT/CT image fusion results were in agreement with the biodistribution results. In conclusion, the human scFv antibodies against ATC were successfully generated, and clear imaging of 131I‑scFv in a nude mouse model at 48 h was obtained.

View Figures

View References

1	Amodeo C, Caglià P, Gandolfo L, Veroux M, Donati M and Immè A: Undifferentiated carcinoma of the thyroid. Tumori. 89:(Suppl 4). S205–S206. 2003.(In Italian).
2	Denaro N, Nigro CL, Russi EG and Merlano MC: The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. Onco Targets Ther. 9:1231–1241. 2013. View Article : Google Scholar : PubMed/NCBI
3	Kihara M, Miyauchi A, Yamauchi A and Yokomise H: Prognostic factors of anaplastic thyroid carcinoma. Surg Today. 34:394–398. 2004. View Article : Google Scholar : PubMed/NCBI
4	Xia J, Bi H, Yao Q, Qu S and Zong Y: Construction of human ScF phage display library against ovarian tumor. JJ Huazhong Univ Sci Technolog Med Sci. 26:497–499. 2006. View Article : Google Scholar
5	McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM and Jacks T: p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci USA. 111:E1600–E1609. 2014. View Article : Google Scholar : PubMed/NCBI
6	Luo Y, Pang H and Li S, Cao H, Peng Z, Fan C and Li S: Production and radioimmunoimaging of novel fully human phage display recombinant antibodies and growth inhibition of lung adenocarcinoma cell line overexpressing Prx I. Cancer Biol Ther. 8:1369–1377. 2009. View Article : Google Scholar : PubMed/NCBI
7	Qiong L, Hua P, Xi J, Li W and Lu X: Medullary thyroid carcinoma like humanized phage single chain antibody screening and identification. Chongqing Yike Daxue Xuebao. 9:12–16. 2015.
8	Duan D, Li SL, Zhu YQ and Wang SB: Effects of radioimmunoimaging with ⁹⁹Tc^m-EGFR-McAb or ⁹⁹Tc^m-CD44-McAb or combined application of both on nude mice bearing human lung adenocarcinoma. J Third Mil Med Univ. 31:1287–1280. 2009.
9	Zhao WS, Luo Y, Li BY, Zhou HJ and Zhang T: Anti-ABCG2 scFv antibody of lung adenocarcinoma increases chemosensitivity and induces apoptosis through the activation of mitochondrial pathway. Am J Cancer Res. 6:1026–1039. 2016.PubMed/NCBI
10	Xi J, Hua P, Sen Z, Qiong L and Li W: Thyroid without differentiation carcinoma of human scFv antibody library construction and screening. J Immunol. 31:692–696. 2015.
11	Smallridge RC, Marlow LA and Copland JA: Anaplastic thyroid cancer: Molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 16:17–44. 2009. View Article : Google Scholar : PubMed/NCBI
12	Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH and Koeffler HP: High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest. 91:179–184. 1993. View Article : Google Scholar : PubMed/NCBI
13	Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL and Tallini G: β-catenin dysregulation in thyroid neoplasms: Down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol. 158:987–996. 2001. View Article : Google Scholar : PubMed/NCBI
14	Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, et al: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 88:5399–5404. 2003. View Article : Google Scholar : PubMed/NCBI
15	Quiros RM, Ding HG, Gattuso P, Prinz RA and Xu X: Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 103:2261–2268. 2005. View Article : Google Scholar : PubMed/NCBI
16	Gui PL and Cheng MZ: Tumor radioimmunoimaging and treatment of a predetermined bit technology. Foreign Medical Oncology. 25:26–29. 1998.
17	Vezzosi D, Bennet A and Caron P: Recent advance in treatment of medullary thyroid carcinoma. Ann Endrocrinol. 68:147–153. 2007. View Article : Google Scholar
18	Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S, Al-Nahhas A and Gross MD: The role of ¹⁸F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: A prospective study. Eur J Surg Oncol. 34:581–586. 2008. View Article : Google Scholar : PubMed/NCBI
19	Subedi GP, Satoh T, Hanashima S, Ikeda A, Nakada H, Sato R, Mizuno M, Yuasa N, Fujita-Yamaguchi Y and Yamaguchi Y: Overproduction of anti-Tn antibody MLS128 single-chain Fv fragment in Escherichia coli cytoplasm using a novel pCold-PDI vector. Protein Expr Purif. 82:197–204. 2012. View Article : Google Scholar : PubMed/NCBI
20	Staelens S, Desmet J, Ngo TH, Vauterin S, Pareyn I, Barbeaux P, Van Rompaey I, Stassen JM, Deckmyn H and Vanhoorelbeke K: Humanization by variable domain resurfacing and grafting on a human IgG₄, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains. Mol Immunol. 43:1243–1257. 2006. View Article : Google Scholar : PubMed/NCBI
21	Vanden Borre P, McFadden DG, Gunda V, Sadow PM, Varmeh S, Bernasconi M, Jacks T and Parangi S: The next generation of orthotopic thyroid cancer models: Immunocompetent orthotopic mouse models of BRAF^V600E-positive papillary and anaplastic thyroid carcinoma. Thyroid. 24:705–714. 2014. View Article : Google Scholar : PubMed/NCBI
22	Yang J, Yu C, Liao L and Liao H: Expression of human insulin like growth factor-1 in Escherichia coli induced by lactose. Strait Med. 22:248–252. 2010.